E1 ReplicatedModerate confidencePEM unclearRCTPeer-reviewedMachine draft
Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial.
Blacker, C V Russell, Greenwood, David T, Wesnes, Keith A et al. · JAMA · 2004 · DOI
Quick Summary
Researchers tested whether a medication called galantamine hydrobromide could help people with ME/CFS by comparing it to a placebo (dummy pill) in 434 patients across multiple countries. After 16 weeks of treatment, the medication did not work better than placebo for relieving fatigue, sleep problems, pain, or overall quality of life. This study shows that galantamine is not an effective treatment for ME/CFS.
Why It Matters
This well-designed trial provides important negative evidence that galantamine—despite theoretical pharmacological rationale—does not benefit ME/CFS patients, helping redirect research away from ineffective treatments and toward more promising therapeutic targets. The study's rigorous methodology and large sample size offer reliable guidance for both clinicians and patients considering medication options for ME/CFS.
Observed Findings
- No statistically significant difference on Clinician Global Impression Scale between any galantamine dose (2.5–10 mg) and placebo after 16 weeks
- No significant differences in Chalder Fatigue Rating Scale scores between treatment and placebo groups
- No significant improvements in sleep quality (Pittsburgh Sleep Quality Index), pain/functional impact (Fibromyalgia Impact Questionnaire), or quality of life (Nottingham Health Profile) with galantamine versus placebo
- Plasma-free cortisol levels and cognitive performance showed no significant differences between groups
- Exploratory regression analysis failed to identify any prognostic factors predicting treatment response
Inferred Conclusions
- Galantamine hydrobromide demonstrates no efficacy over placebo for treating the core symptoms of ME/CFS
- Despite theoretical pharmacological rationale, acetylcholinesterase inhibition does not appear to be a viable treatment strategy for ME/CFS
- The heterogeneity of ME/CFS may obscure treatment effects in certain patient subgroups, though no identifiable subgroup characteristics predicted response in this trial
Remaining Questions
- Why did galantamine fail to show benefit despite theoretical pharmacological rationale for acetylcholine pathway involvement in CFS?
What This Study Does Not Prove
This study does not prove that no pharmacological treatment for ME/CFS exists, only that galantamine specifically is ineffective. It also does not establish whether other acetylcholine-modulating drugs might be beneficial, nor does it explain why theoretical properties of galantamine failed to translate into clinical benefit. The negative result in this population does not rule out potential benefits in ME/CFS subgroups not adequately represented in this trial.
Tags
Symptom:Cognitive DysfunctionUnrefreshing SleepPainFatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case Definition
Metadata
- DOI
- 10.1001/jama.292.10.1195
- PMID
- 15353532
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →